OpenAI and Moderna announced the pair have expanded their partnership to offer the pharma giant's employees access to ChatGPT Enterprise, a platform that allows customizable GPTs to be developed for a specific purpose. 

Through ChatGPT Enterprise, users can create GPTs by beginning a conversation with ChatGPT, then providing extra knowledge on a subject or giving it instructions. Users can also choose what the GPT can do, such as analyzing data, searching the web or making images. 

Moderna, which initially partnered with OpenAI in early 2023, tested the deployment of ChatGPT Enterprise within its workforce, allowing individual teams to create novel use cases and GPTS to fit their teams' needs. 

Within two months of adopting ChatGPT Enterprise, Moderna said it had 750 GPTs created across the company, every user had 120 conversations through the platform per week on average, and 40% of users created GPTs.

The pharma company will now deploy ChatGPT Enterprise to thousands of its employees through the expanded partnership.

"We believe very profoundly at Moderna that ChatGPT and what OpenAI is doing is going to change the world. We’re looking at every business process – from legal, to research, to manufacturing, to commercial – and thinking about how to redesign them with AI," Stéphane Bancel, CEO of Moderna, said in a statement. 

THE LARGER TREND

OpenAI rolled out ChatGPT Enterprise to the public in November of last year. General users can create a tailored version of ChatGPT to help with specific tasks or activities of daily living, such as becoming a better cook or becoming a better negotiator. 

Experts believe ChatGPT has a great deal of promise in drug discovery through combining natural language processing with innovative drug development. Still, limitations exist, such as ChatGPT being unexplainable, meaning the source of its predictive outcomes cannot be traced. 

Additionally, data within the current version of ChatGPT is not up to date.

OpenAI's website states, "ChatGPT is not connected to the internet, and it can occasionally produce incorrect answers. It has limited knowledge of the world and events after 2021 and may also occasionally produce harmful instructions or biased content."

Despite the limitations, numerous digital health companies are utilizing ChatGPT within their offerings. Hyro, a maker of a GPT-enabled conversational AI provider for healthcare, raised $20 million in Series B funding last year, bringing the company's total funding to $35 million.